Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(11%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
4
44%
Ph early_phase_1
1
11%
Ph phase_1
1
11%
Ph not_applicable
2
22%
Ph phase_3
1
11%

Phase Distribution

2

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
1(11.1%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
4(44.4%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(2)

Detailed Status

Completed5
unknown2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (11.1%)
Phase 11 (11.1%)
Phase 31 (11.1%)
Phase 44 (44.4%)
N/A2 (22.2%)

Trials by Status

completed556%
withdrawn111%
recruiting111%
unknown222%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_4

NATural Ovarian Stimulation

NCT02892942
recruitingphase_4

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
unknownnot_applicable

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

NCT05751681
unknownnot_applicable

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

NCT04308343
completedearly_phase_1

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02892942Phase 4

NATural Ovarian Stimulation

Completed
NCT04671966Phase 4

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Recruiting
NCT05751681Not Applicable

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

Unknown
NCT04308343Not Applicable

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

Unknown
NCT02042196Early Phase 1

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

Completed
NCT01109888Phase 1

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Withdrawn
NCT02333253Phase 3

Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase

Completed
NCT00298025Phase 4

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

Completed
NCT00439829Phase 4

Synchronization of Follicle Wave Emergence and Ovarian Stimulation

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9